A protein called CD47 that helps damaged cells avoid destruction by the immune system may be contributing to severe cases of Covid-19, researchers suggested in a report. In other news, Gilead Sciences Inc.’s intravenous antiviral drug remdesivir helped keep high-risk Covid-19 patients out of the hospital in a randomized trial.

Eli Lilly and Co. and partner Incyte Corp. said on Aug. 3 additional results from a late-stage study showed their Covid-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.

The U.S. health regulator expanded the emergency use authorization for Eli Lilly’s baricitinib for Covid-19, saying the arthritis medicine could now be used without taking Gilead’s drug remdesivir along with the product.

Gilead Sciences Inc. said an analysis showed the company’s antiviral remdesivir reduced mortality rates in hospitalized patients with Covid-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment.

Russia’s Supreme Court on May 27 rejected a lawsuit from Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market the anti-Covid-19 drug remdesivir without the U.S. company ‘s consent.

U.S. drugmaker Merck & Co. joined Gilead Sciences Inc. on April 27 in lending support to India as the world’s second-most populous country scrambles to address drug shortages and bring a raging new wave of Covid-19 cases under control.

Emergent BioSolutions’ Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19 showed that the addition of the treatment to Gilead Sciences’ remdesivir did not provide clinical benefit compared to standard of care plus placebo in hospitalized adult COVID-19 patients with symptoms for less than 12 days.

Genentech reported that the company’s rheumatoid arthritis drug Actemra failed to hit the primary endpoint in a Covid-19 trial, while Vir and GlaxoSmithKline’s antibody against Covid-19 demonstrated 85 percent efficacy.

Swiss drugmaker Roche said on March 11 adding the company’s drug Actemra to Gilead Sciences’ Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe Covid-19 pneumonia.

BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.